Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Strategic Updates

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company, has released its preliminary financial results for the fourth quarter and full year 2025, alongside strategic priorities for 2026. The company, known for its innovative therapies targeting the complement system, highlighted significant commercial and pipeline progress in its latest SEC 8-K filing. Financial Highlights For the full year 2025, Apellis reported preliminary U.S. net product revenues of approximately $689 million. The company's flagship product, SYFOVRE® (pegcetacoplan injection), generated approximately $587 million in U.S. net product revenues, with $155 million coming from the fourth quarter alone. EMPAVELI® (pegcetacoplan) contributed approximately $102 million in U.S. net product revenues for the year, with $35 million in the fourth quarter. As of December 31, 2025, Apellis had approximately $466 million in cash and cash equivalents. Business and Operational Highlights Apellis reported a 17% year-over-year growth in total injection demand for SYFOVRE, maintaining its position as the market leader in geographic atrophy (GA) with a 60% market share. The company delivered approximately 102,000 SYFOVRE doses to physician offices in the fourth quarter, including 89,000 commercial doses and 13,000 free goods doses. Additionally, Apellis announced new five-year data from the GALE extension study, showing that SYFOVRE delayed the progression of GA by approximately 1.5 years in patients with nonsubfoveal GA.EMPAVELI saw a strong launch in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), with 267 new patient start forms in 2025, representing more than 5% market penetration. The company also initiated pivotal trials for EMPAVELI in two additional nephrology indications, focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF). Strategic Initiatives and Corporate Developments Apellis is advancing several strategic initiatives, including the development of a best-in-class prefilled syringe for SYFOVRE, with regulatory submission planned for the first half of 2026. The company is also developing OCT-F, an AI imaging tool designed to visualize functional decline and quantify treatment impact, expected to be available for research use in retina specialist practices in the second half of 2026. Additionally, a Phase 2 study of SYFOVRE combined with APL-3007 is ongoing, with topline data expected in 2027. Management's Perspective Cedric Francois, M.D., Ph.D., CEO of Apellis, emphasized the company's significant strides in 2025, highlighting focused execution and meaningful commercial and pipeline progress. He noted the strong momentum heading into 2026, with priorities including expanding the geographic atrophy market and advancing initiatives to strengthen SYFOVRE's competitive position. Francois also pointed out EMPAVELI's progress towards blockbuster status and the company's strong balance sheet, which positions Apellis to self-fund its pipeline and drive long-term sustainable value creation. Future Outlook Looking ahead, Apellis projects that its cash and cash equivalents, combined with expected product revenues, will be sufficient to fund operations to profitability. The company plans to submit a regulatory application for a prefilled syringe for SYFOVRE in the first half of 2026 and expects to make OCT-F available for research use in the second half of 2026. Additionally, Apellis anticipates topline data from the Phase 2 study of SYFOVRE + APL-3007 in 2027.Original SEC Filing: Apellis Pharmaceuticals, Inc. [ APLS ] - 8-K - Jan. 12, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.